What’s New

Activity Overview

The 2023 Symposium focused on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines recent data, application of new tools and evidence on current practice with information that might be applied in the future.

Target Audience

This activity is designed for an audience of pharmacists, physicians, physician assistants and nurses.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

• Identify and articulate the major challenges faced in the fields of diagnosis, prognosis, and therapy in MDS.
• Identify the key diagnostic criteria used in various MDS classification systems, including factors such as bone marrow morphology, cytogenetics, and clinical parameters.
• Assess the clinical implications of diagnosing pre-MDS states, including the need for regular monitoring, patient education, and informed decision-making regarding treatment options.
• Review the concept of lower-risk myelodysplastic syndromes (LR-MDS), including the clinical and hematological characteristics that define this subgroup.
• Explore various AI applications in MDS practice, such as risk stratification, diagnosis, treatment response prediction, and personalized treatment recommendations.
• Explore the importance of tailoring treatment approaches to individual patients, especially in the case of higher risk diseases.
• Review relevant clinical studies and trials that investigate the impact of cytoreduction on transplant outcomes.
• Utilize critical thinking skills to prioritize potential diagnoses, ruling them in or out systematically using clinical reasoning.